StockUS listing USKROSNASDAQHealthcareQuality Compounder

Keros Therapeutics Inc(KROS) Stock Analysis | Healthcare

USD --+0.00%
Reward64Moderate
Risk35Moderate
75%Data
Thin -151% profit margin · Revenue growing 181% YoY
USD —+0.00 (+0.00%) Previous close · NASDAQ
Market cap 217.44M
Reward Ratingⓘ64 Moderate reward assessment · 75% data coverage
Top 50% of stocksView factors
Risk Ratingⓘ35 Moderate risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on KROS to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Keros Therapeutics Inc?

, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States.

AI Brief Pro

The brief on Keros Therapeutics Inc

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Keros Therapeutics Inc?

, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 217.44M.

Financial Highlights

Investment Breakdown

Growth
Revenue and earnings growing steadily, indicating improving operating performance.
Profitability
Strong margins and consistent earnings support financial stability.
Risk
Below-average volatility supports a steadier risk profile.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (64)
Company Information
SectorHealthcare
IndustryBiotechnology
Market Cap217.44M
Beta1.187
Insider Activity
12M windowBearish
Shares soldShares bought
0-3months
51,700 shares
$18k
0
3-6months
818,253 shares
$191k
33,000 shares
$31k
6-9months
0
34,000 shares
$45k
9-12months
17,015 shares
$113k
0